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We have previously demonstrated that DT-010, a novel conjugate of danshensu (DSS)
and tetramethylpyrazine (TMP), displays anti-tumor effects in breast cancer cells both
in vitro and in vivo. In the present study, we investigated whether DT-010 enhances
the chemotherapeutic effect of doxorubicin (Dox) in MCF-7 breast cancer cells and
exerts concurrent cardioprotective benefit at the same time. Our findings showed that
DT-010 was more potent than TMP, DSS, or their combination in potentiating Dox-
induced toxicity in MCF-7 cells. Co-treatment with DT-010 and Dox increased apoptosis
in MCF-7 cells relative to Dox alone. Further study indicated that glycolytic capacity,
glycolytic reserve and lactate level of MCF-7 cells were significantly inhibited after
DT-010 treatment. DT-010 also increased the expression of the pro-survival protein
GRP78, which was inhibited by co-treatment with Dox. Both endoplasmic reticulum
stress inhibitor 4-PBA and knockdown of the expression of GRP78 protein potentiated
DT-010-mediated apoptosis in MCF-7 cells. Moreover, DT-010 inhibited Dox-induced
cardiotoxicity in H9c2 myoblasts. In conclusion, DT-010 and Dox confer synergistic
anti-tumor effect in MCF-7 breast cancer cells through downregulation of the glycolytic
pathway and inhibition of the expression of GRP78. Meanwhile, DT-010 also protects
against Dox-induced cardiotoxicity.
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INTRODUCTION
Doxorubicin, an antibiotic classified as belonging to the anthracycline group, is one of the most
effective broad-spectrum anti-cancer drugs and is extensively used for the treatment of many types
of cancers including breast cancer, prostate cancer, and ovarian cancer. However, many side effects,
especially dose-dependent and cumulative cardiotoxicity, often limit its clinical use (Swain et al.,
2003). To minimize its toxicity in heart, and multidrug resistant response in cancer cells, many
strategies – such as combination with other anti-cancer or cardioprotective drugs – have been tried
(Das et al., 2010; Demetri et al., 2012).
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FIGURE 1 | Synergistic anti-tumor effect of DT-010 and Dox on MCF-7
breast tumor cells. (A) Chemical structures of DSS, TMP, and DT-010
(Wang et al., 2016). (B) Cell numbers of MCF-7 cells were determined after
DT-010 and different concentrations of Dox treatment. (C) MCF-7 cells were
treated with different concentration of DSS, TMP, D+T (DSS+TMP), DT-010
and Dox (1 µM) for 24 h, and cell numbers were then counted. #P < 0.05 vs.
Ctrl and ∗P < 0.05 vs. Dox.
Aerobic glycolysis refers to the process of transformation of
glucose in to lactate in the presence of limited oxygen. Many
types of cancer cells exhibit enhanced aerobic glycolysis to
meet energy demand and macromolecular biosynthesis, which
partly depends on factors such as hypoxia and impairment of
mitochondrial respiration (Zheng, 2012; Ganapathy-Kanniappan
and Geschwind, 2013). Studies have shown that inhibition of
glycolysis decreases ATP production, induces cancer cell death
and increases the sensitivity of cancer cells to chemotherapeutic
agents, indicating that glycoysis is a promising target for cancer
therapy (Xu et al., 2005; Pelicano et al., 2006; Finley et al., 2011;
Liu et al., 2014).
The endoplasmic reticulum (ER) plays a major role in
promoting protein folding and maintaining cellular calcium
homeostasis. Under cellular stress conditions such as oxidative
stress, hypoxia and nutrient deprivation, the unfolded or
misfolded proteins may accumulate in the ER, leading to
ER stress (Verfaillie et al., 2013). Several studies showed ER
stress is implicated in the modulation of glycolysis. ATF-
4 (activating transcription factor 4), an ER stress response
factor, was demonstrated as a transcriptional regulator of
glycolysis (Lee et al., 2015). 2-DG (2-deoxy-D-glucose) is an
inhibitor of glycolysis, which also induces ER stress (Yu and
Kim, 2010). GRP78, a regulator of ER stress, is associated
with aerobic glycolysis in cancer cells (Li et al., 2015).
Many kinds of cancer cells exhibit increased expression of
GRP78 protein in the tumor microenvironment, resulting in
tumor survival, metastasis and resistance to chemotherapy
(Lee, 2007). Thus, inhibition of GRP78 is a strategy to
overcome chemotherapeutic resistance and improve cancer
therapy.
Our previous findings indicated that a DSS and
tetramethylpyrazine (TMP) derivative, DT-010, was more
potent than their parental compounds or their combination in
inhibiting proliferation of breast cancer cells both in vitro and
in vivo by targeting mitochondrial complex II (Wang et al., 2016).
In this study, we will investigate whether DT-010 enhances the
chemotherapeutic effect of Dox in MCF-7 breast cancer cells and
its underlying mechanisms. Furthermore, the cardioprotective
effects of DT-010 against Dox-induced cardiotoxicity will also be
determined.
MATERIALS AND METHODS
Materials
DT-010 (purity > 98%, Figure 1A) were synthesized at Jinan
University, China (Scheme 1). TMP and DSS (Figure 1A)
were purchased from Shanghai Banghai Chemical Company
(China) and Xi’an Honson Biotechnology (China), respectively.
The Dulbecco’s Modified Eagle’s Medium (DMEM), penicillin-
streptomycin and fetal bovine serum (FBS) used in this
study were obtained from Life Technologies (USA). 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazoliumbromide (MTT)
was purchased from Sigma-Aldrich (USA). GRP78 siRNA was
provided by Santa Cruz Biotechnology (USA). An XF Glycolysis
Stress Test Kit was purchased from Seahorse Bioscience (USA).
Lactate assay kit was purchased from BioVision (USA).
Scheme 1 Synthesis of DT-010. Reagents and conditions: (a)
KMnO4, 45◦C, overnight, 50%; (b) CH3CH2OH, EDCI, DMAP,
r.t., 84%; (c) C3H5MgBr, THF, 0◦C to r.t., 34%; (d) Ac2O, HClO4,
r.t., 3 h, 36%; (e) C2Cl2O2, DMF, CH2Cl2; (f) n-C4H9Li, THF, 0◦C
to r.t., 41%; (g) Na2CO3, CH3OH, H2O, 82%.
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FIGURE 2 | DT-010 enhanced Dox induced apoptosis in MCF-7 cells. (A) Representative images of the cell morphology of MCF-7 cells. (B) Representative
images of apoptotic cells in MCF-7 cells, which were stained with Hoechst33342. Dotted and solid arrows indicate the normal cells and apoptotic cells with
chromatin condensation, respectively. Scale bar: 50 µm. (C) The percentage of apoptotic cells in MCF-7 cells after 24 h of DT-010 and Dox treatment. (D) The
expression of p53, PARP and cleaved-PARP proteins in MCF-7 cells were determined by Western blot after 24 h of Dox treatment in the presence or absence of
DT-010. (E,F) Densitometric quantification of the expression of cleaved-PARP and p53 protein.#P < 0.05 vs. Ctrl and ∗P < 0.05 vs. Dox.
Cell Culture
MCF-7 and H9c2 cells were cultured in DMEM medium
with 10% FBS at 37◦C in an incubator containing 5% CO2
and 95% air. Cells were used until they reached 70–80%
confluence.
Measurement of Cell Viability, Cell
Numbers, and Apoptosis
Cell viability was assessed by MTT assay. Briefly, H9c2 cells
were cultured in 96 well plates for 24 h. After 24 h of treatment
with Dox in the absence or presence of DT-010, cells were
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FIGURE 3 | DT-010 blocked glycolytic pathway of MCF-7 cells. MCF-7 cells were treated with DT-010 for 12 h, and the ECAR (A) and OCR (B) were measured
with XF24 extracellular flux analyzer. ∗P < 0.05 vs. DT-010 treated group. (C,D) The glycolytic capacity and glycolytic reserve in MCF-7 cells were calculated.
#P < 0.05 vs. Ctrl. (E) MCF-7 cells were treated with DT-010 for 12 h. Levels of lactate were measured according to lactate assay kit. #P < 0.05 vs. Ctrl.
incubated in medium containing 1 mg/ml MTT. The formazen
was then dissolved with 100 µl DMSO after incubation at
37◦C. SpectraMax M5 Microplate Reader was used to detect
the absorbance at 570 nm. Cell numbers were determined as
described previously (Wang et al., 2015). Briefly, MCF-7 cells
were cultured in 96-well plates for 24 h. After treatment with
DT-010 and DT-010 for 24 h, cells were stained with DAPI and
then visualized by the In Cell Analyzer 2000 system. The number
of cells was calculated using Developer Toolbox software. For
apoptosis assay, MCF-7 cells were stained with Hoechst 33342
for 15 min to measure apoptotic cells. The apoptotic cells with
changes in chromatin condensation were analyzed by the In Cell
Analyzer 2000 system.
Determination of Metabolic Parameters
MCF-7 cells at a density of 1 × 104 cells/well were cultured in
24-well tissue microplates (Seahorse) for 24 h (Each group has at
least three wells). After 12 h of DT-010 treatment, the medium
was then replaced with Seahorse base medium (pH = 7.4) and
placed the plate into 37◦C non-CO2 incubator for 1 h. The ECAR
and OCR values were measured before and after the injection of
metabolic reagents from the XF Glycolyis Stress Test Kit.
Evaluation of Lactate Level
MCF-7 cells were plated in 96-well plates at a density of 6 × 103
cells/well. After 12 h of DT-010 treatment, the production of
lactate in culture medium was measured using Lactate assay kit
(BioVision) and normalized to the number of cells.
Western Blot Analysis
Cells lysate was extracted as previously report (Wang et al.,
2015). Briefly, MCF-7 cells were washed with PBS and lysed by
cell lysis buffer supplemented with 1% phenylmethanesulfonyl
fluoride and 1% cocktail. After 30 min of incubation on ice,
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FIGURE 4 | Dox inhibited DT-010-induced GRP78 expression in MCF-7 cells. Immunoblots (A) and densitometric analysis (C) of the expression of GRP78
protein were determined after DT-010 treatment in MCF-7 cells. (B) MCF-7 cells were treated with DT-010 for 24 h in the presence or absence of Dox.
Representative immunoblots for the expression of GRP78 and β-actin proteins were exhibited. (D) Densitometric analysis showed the expression of GRP78 protein.
#P < 0.05 vs. Ctrl.
the samples were centrifuged (12,000 × g) for 20 min at
4◦C. The concentration of supernatant proteins was measured
according to the protocol for BCA protein assay (Thermo
Scientific). After being denatured at 95◦C for 5 min, proteins were
then separated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGD) and transferred to polyvinylidene
fluoride membrane using semi-dry protein transfer. The
membrane was block by 5% milk for 1 h and incubated
with primary antibodies against β-actin, cleaved-PARP, p53
(Cell Signaling) and GRP78 (Santa Cruz Biotechnology). After
incubation at 4◦C overnight, the membrane was incubated
with secondary antibodies (Cell Signaling) for 1 h at room
temperature. Finally, the advanced enhanced ECL system (GE
Healthcare) was used to detect the immune complexes and the
bolts were quantified by Quantity One software (Bio-Rad).
Statistical Analysis
Data are shown as mean ± standard deviation (SD). Differences
among the groups were compared by one-way ANOVA followed
by Turkey’s multiple comparison tests. P < 0.05 was considered
as statistically significant.
RESULTS
DT-010 and Dox Display Synergistic
Anti-tumor Effects against MCF-7 Breast
Tumor Cells
As shown in Figure 1B, the numbers of MCF-7 cells were
significantly decreased after 24 h of Dox (1 µM) treatment, and
were further reduced after DT-010 treatment. Co-treatment with
DT-010 and Dox was more potent than DSS, TMP, DSS+TMP,
and Dox combination in inducing cell death of MCF-7 cells
(Figure 1C).
DT-010 Increases Dox-Induced
Apoptosis of MCF-7 Cells
To investigate whether DT-010 increases Dox-induced apoptosis
in MCF-7 cells. MCF-7 cells were co-treated with DT-010 and
Dox for 24 h. Figure 2A shows that co-treatment with Dox and
DT-010 for 24 h changes cell morphology as compared with Dox
treated group. Dox treatment alone induced apoptosis in MCF-7
cells, and the combination of DT-010 and Dox further increased
cell apoptosis (Figures 2B,C). This is consistent with the data
showing that the expression of apoptosis-related proteins p53 and
cleaved-PARP increased after Dox treatment (Figures 2D–F),
which was further amplified after DT-010 and Dox co-treatment.
DT-010 Blocks Glycolytic Pathway in
MCF-7 Cells
The effects of DT-010 on the glycolysis of MCF-7 cells were
investigated. The changes of ECAR and OCR were monitored
by the Seahorse XF Extracellular Flux Analyzer. As shown in
Figures 3A,C,D, the glycolytic capacity and glycolytic reserve
significantly decreased after DT-010 treatment. DT-010 also
inhibits the basic level of OCR in MCF-7 cells (Figure 3B),
which is consistent with our previous study, showing that DT-010
inhibits mitochondrial respiration in breast cancer cells. Further
study showed DT-010 treatment inhibited the level of lactate in
culture medium (Figure 3E).
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FIGURE 5 | Inhibition of GRP78 expression enhanced DT-010-induced cell apoptosis in MCF-7 cells. (A) The percentage of apoptotic cells in MCF-7 cells
was recorded after 24 h of DT-010 treatment in the presence or absence of ER stress inhibitor 4-PBA. #P < 0.05 vs. DT-010 treated group. (B) MCF-7 cells were
treated with Dox and DT-010 for 24 h, the expression of p53, cleaved-PARP, β-actin proteins were measured by western blot. The expression of GRP78 protein was
determined after 12 h of Dox and DT-010 treatment. Representative immunoblots for the expression of p53, cleaved-PARP, β-actin and GRP78 proteins.
(C) Densitometric quantification of the expression of GRP78 protein. (D) GRP78 knockdown further promotes DT-010-induced cell death in MCF-7 cells. ∗ means
significant difference between treatments (P < 0.05).
Dox Inhibits DT-010-Induced GRP78
Expression in MCF-7 Cells
The effects of DT-010 on GRP78 expression in MCF-7 cells
were determined. Images of immunoblots in Figure 4A and
densitometric analysis in Figure 4C showed that DT-010
increased the expression of GRP78 protein in a time dependent
manner. Previous study showed that Dox prevented ER stress
inducer-mediated GRP78 expression (Kim et al., 2006). In this
study, we examined the effect of Dox on DT-010-induced GRP78
expression in MCF-7 cells. DT-010 treatment promoted the
expression of GRP78 protein, which was inhibited by Dox and
DT-010 co-treatment (Figures 4B,D).
Inhibition of GRP78 Expression
Enhances DT-010-Induced Cell
Apoptosis
To determine whether there were synergistic anti-tumor effects
of DT-010 in combination with Dox via the inhibition of GRP78
expression, MCF-7 cells were co-treated with DT-010 and the
ER stress suppressor, 4-PBA. DT-010 and 4-PBA co-treatment
markedly increased apoptosis in MCF-7 cells as compared with
DT-010 or 4-PBA treated alone (Figure 5A). Similarly, 4-PBA
potentiated DT-010-induced expression of the apoptosis-related
proteins p53 and cleaved-PARP, and suppressed DT-010-induced
expression of GRP78 protein (Figures 5B,C). Moreover, GRP78
knockdown using siRNA significantly reduced cell viability after
DT-010 treatment relative to DT-010 alone (Figure 5D).
DT-010 Protects against Dox-Induced
Cardiotoxicity in H9c2 Cells
The effects of DT-010 on Dox-induced toxicity were investigated
in this study. Figures 6A,B indicate that DT-010 exposure alone
showed no toxicity at concentrations below 20 µM as detected
by LDH assay and MTT assay. Further study indicates Dox
causes cytotoxicity and decreases cell viability in H9c2 cells,
while DT-010 co-treatment reduces LDH release (Figure 6C) and
preserves cell viability (Figure 6D) in a dose-dependent manner
as compared with the DT-010 treated group. These data suggest
that DT-010 inhibits Dox-mediated cardiotoxicity in H9c2 cells.
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FIGURE 6 | DT-010 protected against Dox-induced toxicity in H9c2 cells. (A,B) H9c2 cells were treated with different concentrations of DT-010 for 24 h and
the toxicity of DT-010 in H9c2 cells was measured by LDH assay and MTT assay, respectively. Dox treatment for 24 h significantly increased the cytotoxicity (C) and
decreased cell viability (D) in H9c2 cells, which were reversed by DT-010 co-treatment. #P < 0.05 vs. Ctrl and ∗P < 0.05 vs. Dox.
DISCUSSION
We have shown that DT-010, a derivative of danshensu (DSS)
and TM), exhibits anti-tumor effects in breast cancer cells
via the inhibition of mitochondrial complex II, resulting in
ROS generation and mitochondrial dysfunction (Wang et al.,
2016). DSS is a major ingredient of Danshen, which is one of
the most commonly used Chinese herbs for the treatment of
cardiovascular disease (Cui et al., 2013; Yin et al., 2013; Yu
et al., 2014). TMP, a major alkaloid ingredient of the Chinese
herb Chuanxiong, shows pharmacological effects such as anti-
oxidation, anti-apoptosis, and protection against ischemic brain
injury (Liao et al., 2004; Juan et al., 2007; Sue et al., 2009).
On the other hand, TMP also displays anti-cancer effects and
overcomes Dox-resistance in MCF-7 breast cancer cells (Zhang
et al., 2012; Yi et al., 2013). Based on previous study, we
further evaluated the potential synergistic anti-tumor effects
of DT-010 with Dox in MCF-7 cells. We found that DT-010
and Dox co-treatment displayed much better anti-tumor effects
than its parental compounds, separately or in combination, in
the presence of Dox. Further study showed that Dox induced
apoptosis in MCF-7 cells, which was further increased after
DT-010 co-treatment.
A growing body of evidence shows that inhibition of
glycolysis may kill cancer cells, overcome multidrug resistance
and enhancing the efficacy of chemotherapeutic agents, thereby
suggesting that glycolysis is a novel target for cancer therapy.
Glycolysis inhibitors such as 2-deoxyglocose, 3-bromopyruvate,
and lonidamine decrease ATP levels in cancer cells and display
anti-cancer effects both in vitro and in vivo (Pelicano et al.,
2006). Overexpression of SIRT3 has been shown to inhibit tumor
proliferation through the repression of glycolysis (Finley et al.,
2011). 2-DG increases the chemotherapeutic efficacy of Dox and
paclitaxel in cancer cells in vivo (Maschek et al., 2004). Inhibition
of glycolysis also enhances the sensitivity of multidrug-resistant
cells to anti-cancer agents (Xu et al., 2005). Our data showed
that DT-010 inhibited glycolytic capacity, glycolytic reserve
and lactate level of MCF-7 cells, improving the anti-cancer
effects of Dox in MCF-7 cells, which is consistent with prior
studies showing inhibition of glycolysis as a relevant strategy for
improving effects of conventional chemotherapeutic drugs such
as Dox.
GRP78 confers chemotherapeutic resistance in a variety of
cancers. Studies showed that suppression of GRP78 enhanced the
anti-cancer effects of etoposide in NCI-H446 cancer cells (Wang
et al., 2008). The anti-cancer effects of etoposide and doxorubicin
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in CHO cells were inhibited after GRP78 overexpression (Reddy
et al., 2003). Moreover, overexpression of GRP78 reduced cells
apoptosis in response to etoposide and cisplatin in glioma cells,
while the down-regulation of GRP78 increased the sensitivity of
glioma cells to etoposide and cisplatin (Lee et al., 2008). In the
present study, we observed that the expression of GRP78 protein
was elevated after DT-010 treatment in MCF-7 cells. Previous
study showed that Dox inhibited the expression of GRP78 protein
and ATF-4 mRNA after treatment with the ER stress inducer
thapsigargin in MCF-7 cells (Kim et al., 2006). We then provided
evidence that the ER stress inhibitor, 4-PBA, decreased the
expression of GRP78 protein and increased apoptosis in MCF-7
cells after DT-010 treatment. Furthermore, knockdown of GRP78
using siRNA potentiated DT-010-induced cell death in MCF-
7 cells. These results indicated that DT-010 and Dox displayed
synergistic anti-tumor effects partly via GRP78 downregulation.
In this study, we also investigated the cardioprotective effects
of DT-010 on Dox-induced cardiotoxicity. The data showed that
Dox triggered toxicity in H9c2 cells, which was significantly
inhibited by DT-010 co-treatment.
CONCLUSION
This study demonstrated that DT-010 and Dox displayed a
synergistic anti-tumor effect in breast cancer cells. Further study
indicated that the anti-tumor effect of DT-010 and Dox was
correlated with the inhibition of glycolysis and GRP78-mediated
pro-survival pathway. Moreover, DT-010 protected against Dox-
mediated cardiotoxicity in H9c2 cells. This study suggested
the potential utility of the DT-010 and Dox combination for
improving the anti-tumor efficacy of Dox in MCF-7 breast cancer
cells.
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